MUC1 as a target antigen for cancer immunotherapy.
The cancer-associated antigen MUC1 is overexpressed and modified by tumor cells in over half of all cancer cases. Despite various complexities associated with this antigen, it is well worth pursuing as a vaccine for the immunotherapy of cancer. In this review, the authors describe the discovery of MUC1 and its association with cancer, recent observations showing that the immunology of MUC1 is complicated, animal data showing that it can be a target for immune-mediated tumor rejection, and finally, preliminary clinical results to show that vaccine-based immunotherapy with MUC1 does have an impact on the therapy of cancer.
Acres
Bruce
B
Department of Medical and Regulatory Affairs, Transgene, 67082 Strasbourg, France. acres@transgene.fr
Limacher
Jean-Marc
JM
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D018396:Mucin-1 / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control*
D019496:Cancer Vaccines; D018396:Mucin-1